What does the evidence show about Semaglutide's effects?

Read Off Label rates the evidence for Semaglutide as Strong and the benefit magnitude as high, producing an overall grade of B (6.8/10). STEP 1: ~15% body weight loss over 68 weeks.

What safety findings are reported for Semaglutide?

Semaglutide has a med risk profile in the database. Med (GI effects; gallbladder/pancreatitis; altered skin sensation more common at Wegovy HD 7.2 mg) Legal status: Rx.

What doses or routes are reported for Semaglutide?

Wegovy obesity label: titration to 2.4 mg SC weekly; Wegovy HD: 7.2 mg SC weekly in selected adults; Ozempic (T2DM): 0.25-2 mg SC weekly This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.

Rankings / Metabolic Health

Semaglutide

Metabolic Health · GLP-1 agonist

Also known as: Ozempic ·Wegovy ·Rybelsus

Tier B

Reviewed by Read Off Label · Last reviewed Jul 11, 2026 · How we grade

glp-1prescription

6.8 / 10

Tier B

Ev 8 Bn 8 Sf 5

Bottom line

Read Off Label grades Semaglutide as B (6.8/10) based on strong evidence, high benefit magnitude, and a med-risk safety profile.

STEP 1: ~15% body weight loss over 68 weeks.

Studied, labeled, or reported-use context: Wegovy obesity label: titration to 2. — Rx; not individualized guidance.

If you were testing this on yourself

Two properties decide whether an n-of-1 experiment is readable and recoverable. These describe the experiment — they are not a judgment about whether to run it, and nothing here is a recommendation.

Can you undo it?

Reverses on stopping

Weight regain after stopping is well documented and substantial, which makes this reversible in the safety sense and not in the outcome sense — the effect reverses too. Lean mass lost during the loss is not automatically regained.

Can you tell if it worked?

Readable — Weeks

Body weight, waist, HbA1c. Very readable.

What would fool you Rapid weight loss without resistance training and adequate protein costs lean mass, which a scale will not distinguish from fat. Track something beyond weight or the readout misleads.

What the evidence says

STEP 1: ~15% body weight loss over 68 weeks. SELECT 2023: 20% reduction in MACE in obese patients with CVD but no diabetes. FDA approved Wegovy HD 7.2 mg on March 19, 2026 after data showed additional average weight reduction vs lower approved doses with a broadly consistent GLP-1 safety profile; altered skin sensation (sensitivity, pain, burning) was more common at the higher dose and is under further FDA investigation. GI side effects common; rare pancreatitis/gallbladder. Weight regain on cessation. Delayed gastric emptying raises peri-operative aspiration risk — anesthesia guidance now recommends holding GLP-1 agonists before elective surgery. Oral Wegovy (semaglutide tablets) is FDA-approved for chronic weight management; Phase 3 OASIS-4 (n=307, 64 wk): ~13.6% weight loss vs 2.4% placebo (treatment-policy estimand). A Jul 2026 BMJ network meta-analysis (262 RCTs, n=99,791) of approved anti-obesity drugs found subcutaneous semaglutide was the only agent in the comparison showing reduced all-cause mortality (RR 0.81) and MI (RR 0.72) -- an independent confirmation of the SELECT mortality signal.

Mechanism

GLP-1 receptor agonist: slows gastric emptying; suppresses glucagon; enhances glucose-dependent insulin secretion; central appetite suppression via hypothalamic GLP-1R

Studied, labeled, or reported dose & route

Wegovy obesity label: titration to 2.4 mg SC weekly; Wegovy HD: 7.2 mg SC weekly in selected adults; Ozempic (T2DM): 0.25-2 mg SC weekly

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Semaglutide's effects?: Read Off Label rates the evidence for Semaglutide as Strong and the benefit magnitude as high, producing an overall grade of B (6.8/10). STEP 1: ~15% body weight loss over 68 weeks.
What safety findings are reported for Semaglutide?: Semaglutide has a med risk profile in the database. Med (GI effects; gallbladder/pancreatitis; altered skin sensation more common at Wegovy HD 7.2 mg) Legal status: Rx.
What doses or routes are reported for Semaglutide?: Wegovy obesity label: titration to 2.4 mg SC weekly; Wegovy HD: 7.2 mg SC weekly in selected adults; Ozempic (T2DM): 0.25-2 mg SC weekly This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Semaglutide work?: GLP-1 receptor agonist: slows gastric emptying; suppresses glucagon; enhances glucose-dependent insulin secretion; central appetite suppression via hypothalamic GLP-1R

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.